FDA Revises Generic Digoxin Guidance Following Concordia Petition

Drug Industry Daily
A A
The FDA revised its near-decade-old guidance on developing generic versions of digoxin tablets, calling for more robust testing. The agency reconsidered the guidance in response to a citizen petition from reference holder Concordia Pharmaceuticals.

To View This Article:

Login

Subscribe To Drug Industry Daily